Access Pharmaceuticals
Operating Status: Closed
Access Pharmaceuticals: An emerging leader in oncology and diabetes, with FDA-approved treatments and ongoing trials.
Founded
1974Access Pharmaceuticals: An emerging leader in oncology and diabetes, with FDA-approved treatments and ongoing trials.
Access Pharmaceuticals, an emerging pharmaceuticals company, was founded with a core mission to develop innovative treatments in the fields of oncology and diabetes. The company offers FDA-approved treatments, including MuGard for oral mucositis, which has been commercially launched in Europe. Additionally, Access Pharmaceuticals is advancing ProLindac, a novel DACH platinum chemotherapy, which has completed a Phase 2a trial in recurrent ovarian cancer and is set to enter combination trials. The company is actively seeking partnerships in North America while already having established collaborations in the Far East.
Notable affiliated individuals and investors have contributed to Access Pharmaceuticals' growth, though specific names are not detailed. Key achievements include the FDA approval and commercial launch of MuGard, as well as significant progress in clinical trials for ProLindac. The company's impact is marked by its commitment to addressing critical needs in oncology and diabetes treatment, positioning it as a promising player in the pharmaceutical industry.
Companies similar to Access Pharmaceuticals include Innocrin Pharmaceuticals, Moksha8, Apexian Pharmaceuticals and NovAccess Global.
Access Pharmaceuticals was founded in 1974.
Access Pharmaceuticals' headquarters is located in Dallas, TX, US.
Access Pharmaceuticals' most recent funding round was for $10M (USD) in November 2012.
As of Nov 6, 2012, Access Pharmaceuticals has disclosed funding of $38.9M (USD). Undisclosed round amounts are excluded.
NovAccess Global
